
Benedetta Conte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9441105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1.	5.2	331
2	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research, 2020, 22, 45.	5.0	175
3	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	7.7	92
4	Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. Cancers, 2020, 12, 2325.	3.7	60
5	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	10.7	52
6	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open, 2018, 3, e000361.	4.5	49
7	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine, 2022, 75, 103801.	6.1	47
8	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast, 2018, 41, 51-56.	2.2	41
9	Update on the Management of Breast Cancer during Pregnancy. Cancers, 2020, 12, 3616.	3.7	37
10	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Clinical Breast Cancer, 2020, 20, e181-e187.	2.4	30
11	Italian survey on managing immune checkpoint inhibitors in oncology during COVIDâ€19 outbreak. European Journal of Clinical Investigation, 2020, 50, e13315.	3.4	28
12	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQqO 1137.	0	Overlock 10
13	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	3.7	17
14	Management of young women with early breast cancer. ESMO Open, 2018, 3, e000458.	4.5	15
15	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. Npj Breast Cancer, 2021, 7, 8.	5.2	14
16	Doseâ€dense adjuvant chemotherapy in HER2â€positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. International Journal of Cancer, 2020, 147, 160-169.	5.1	12
17	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. British Journal of Cancer, 2020, 122, 1611-1617.	6.4	12
18	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125.	7.0	9

Benedetta Conte

#	Article	IF	CITATIONS
19	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. European Journal of Cancer, 2020, 136, 43-51.	2.8	6
20	De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 2021, , .	2.4	6
21	Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1357-1362.	1.8	5
22	Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy. Breast Cancer Research and Treatment, 2018, 171, 245-246.	2.5	3
23	Conadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients. Minerva Obstetrics and Gynecology, 2017, 69, 350-356.	1.0	3
24	Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. In Vivo, 2021, 35, 635-639.	1.3	2
25	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori, 2022, , 030089162110675.	1.1	1